Primary Aldosteronism and Ischemic Heart Disease

Area of Science:

• Cardiology
• Endocrinology
• Hypertension Research

Background:

• Cardiovascular disease, especially ischemic heart disease (IHD), is a leading global cause of death.
• Primary aldosteronism (PA) is the most common cause of secondary hypertension but is frequently underdiagnosed.
• Emerging evidence suggests PA contributes to IHD risk independently of its hypertensive effects.

Purpose of the Study:

• To highlight the significant association between excess aldosterone and increased IHD burden.
• To elucidate the pathophysiological mechanisms linking aldosterone to cardiovascular damage.
• To emphasize the importance of recognizing PA for improved patient outcomes.

Main Methods:

• Review of recent scientific literature and clinical studies.
• Analysis of aldosterone's genomic and non-genomic cardiovascular effects.
• Comparison of IHD risk in PA versus essential hypertension.

Main Results:

• Excess aldosterone production is linked to a disproportionately high burden of IHD.
• Aldosterone exerts detrimental cardiovascular effects through both genomic and non-genomic pathways.
• PA represents a significant, yet often overlooked, preventable risk factor for cardiovascular morbidity and mortality.

Conclusions:

• Primary aldosteronism significantly elevates ischemic heart disease risk through mechanisms beyond hypertension.
• Early diagnosis and management of PA are critical for mitigating cardiovascular complications.
• Further research into PA pathophysiology can guide targeted therapeutic strategies to reduce cardiovascular events.